<b>GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis</b> - Supplemental Material.pdf

Context: Individuals with psychiatric disorders have a higher prevalence of obesity, partly because of the use of psychotropic medications. Safe and effective pharmacological interventions for weight management in this population are needed.Objective: To assess the efficacy and safety of GLP-1RAs in individuals with psychiatric disorders and obesity/overweight through a systematic review and meta-analysis, focusing on weight and metabolic outcomes.Data Sources: We searched PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov until May 2025 for observational studies that evaluated GLP-1RAs in this population.Study Selection: Studies including adults with psychiatric disorders and obesity treated with GLP-1RAs were eligible; ten RCTs met the inclusion criteria.Data Extraction: Two reviewers independently extracted the data and assessed the risk of bias using the Cochrane RoB 2 tool. Outcomes included weight, body mass index (BMI), waist circumference, glucose level, systolic blood pressure, total cholesterol, HDL cholesterol, triglycerides and adverse events.研究背景：合并精神障碍的个体肥胖患病率更高，部分原因为精神科药物的使用。目前该人群亟需安全有效的体重管理药物干预方案。 研究目的：通过系统综述与荟萃分析，评估胰高血糖素样肽-1受体激动剂（GLP-1RAs）在合并肥胖/超重的精神障碍个体中的疗效与安全性，重点关注体重及代谢相关结局指标。 数据来源：截至2025年5月，我们在PubMed、Embase、Cochrane CENTRAL及ClinicalTrials.gov数据库中检索了评估该人群使用GLP-1RAs的观察性研究。 研究筛选：纳入接受GLP-1RAs治疗、合并精神障碍与肥胖的成年人群相关研究；最终有10项随机对照试验（RCTs）符合纳入标准。 数据提取：由2名研究者独立完成数据提取，并采用Cochrane偏倚风险评估工具2（RoB 2）评估研究偏倚风险。结局指标包括体重、体质量指数（BMI）、腰围、血糖水平、收缩压、总胆固醇、高密度脂蛋白胆固醇、三酰甘油及不良事件。